Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
Safety relevant information on Beta interferons: Risk of thrombotic microangiopathy and nephrotic syndrome
2014.08.20
Active substance: interferon beta
In accord with the European Medicines Agency (EMA) and the marketing authorisation holders, the BfArM issues important safety information regarding the treatment of multiple sclerosis with medicinal products containing interferon beta.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN